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Abstract 49 
Many normal tissues undergo age-related drift in DNA methylation, providing a quantitative 50 
measure of tissue age. Here we identify and validate 781 CpG-islands (CGI) that undergo 51 
significant methylomic drift in 232 normal colorectal tissues and show that these CGI continue to 52 
drift in neoplasia while retaining significant correlations across samples. However, compared 53 
with normal colon, this drift advanced (~3-4 fold) faster in neoplasia, consistent with increased 54 
cell proliferation during neoplastic progression. The observed drift patterns were broadly 55 
consistent with modeled adenoma-carcinoma sojourn time distributions from colorectal cancer 56 
(CRC) incidence data. These results support the hypothesis that, beginning with the founder 57 
premalignant cell, cancer precursors frequently sojourn for decades before turning into cancer, 58 
implying that the founder cell typically arises early in life. At least 77-89% of the observed drift 59 
variance in distal and rectal tumors was explained by stochastic variability associated with 60 
neoplastic progression, while only 55% of the variance was explained for proximal tumors. 61 
However, gene-CGI pairs in the proximal colon that underwent drift were significantly and 62 
primarily negatively correlated with cancer gene expression, suggesting that methylomic drift 63 
participates in the clonal evolution of CRC. Methylomic drift advanced in colorectal neoplasia 64 
consistent with extended sojourn time distributions, which accounts for a significant fraction of 65 
epigenetic heterogeneity in CRC. Importantly, these estimated long-duration premalignant 66 
sojourn times suggest that early dietary and lifestyle interventions may be more effective than 67 
later changes in reducing CRC incidence. 68 
 69 
Statement of Significance 70 
Findings present age-related methylomic drift in colorectal neoplasia as evidence that 71 
premalignant cells can persist for decades before becoming cancerous. 72 
 73 
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Introduction 74 
Colorectal cancers (CRC) arise along alternative pathways through an accumulation of 75 
mutations and epigenetic alterations accompanied by clonal expansions, along with random and 76 
selective drift (1-5). Several mutations or epigenetic changes are thought to be necessary (e.g. 77 
bi-allelic inactivation of APC, epigenetic silencing of MLH1) to initiate premalignant clonal growth 78 
(6). Occult premalignant clones that do not undergo extinction may grow into observable 79 
adenoma while accumulating (epi)genetic alterations, with some developing genomic instability, 80 
undergoing malignant transformation and invasive growth (7-9). Rates for these processes may 81 
be influenced by obesity, diet, genetics, the microbiome and other factors (3, 10-12). Although 82 
CRC genomes have been extensively profiled for somatic mutations, chromosomal 83 
abnormalities and epigenetic alterations (3, 9), little is known about the dynamics of the 84 
carcinogenic process, including the sojourn time distribution from the time when a premalignant 85 
founder cell is born to when the descendent cancer becomes clinically identifiable (13). Here we 86 
aim to better understand these dynamics and the role of epigenetic drift in the colon and rectum 87 
as an indicator of tissue aging and its potential phenotypic effects in colorectal neoplasia (14-88 
16).  89 
Recently, we established a key role of differential methylomic drift in the progression of 90 
Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) by analyzing age-related 91 
differences in DNA methylation between normal esophageal epithelium, metaplastic BE tissue 92 
and EAC tissue (17, 18). Here we define methylomic, or epigenetic, drift to represent the tissue-93 
specific and age-related increases in DNA methylation at certain CpG dinucleotides. One major 94 
finding of this earlier analysis was that epigenetic drift is widespread in BE genomes with the 95 
magnitude of drift being highly variable between individuals, suggesting significant differences in 96 
BE tissue age. We also observed a significant negative correlation of advanced methylomic drift 97 
at the CpG-island (CGI) level with the expression of 200 genes, including several genes that 98 
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have recently been proposed as diagnostic markers for BE or have been implicated in 99 
esophageal carcinogenesis (19, 20).  100 
Epigenetic drift in the colon has been previously identified at a number of genes, in 101 
particular at promoter-associated CpG island (CGI) (14, 21-23). However, methylomic tissue 102 
aging has only recently been studied more extensively in colon, using advanced statistical 103 
regression methods (24, 25) applied to data from high-throughput techniques such as reduced 104 
representation bisulfite sequencing (RRBS) and high-density DNA-methylation arrays.  105 
 106 
Materials and methods 107 
In this study, we used a conventional regression approach geared toward a fuller assessment of 108 
methylomic drift both at the single CpG and CGI level and, for the first time, provide a genome-109 
wide evaluation of methylomic drift in colon (left/right) and rectum from normal and neoplastic 110 
tissue biopsies. We evaluated methylation levels at 450,000  CpG probes using the Illumina 111 
HM450 beadchip array (HM450) in a total of 675 colorectal tissue samples. Of particular interest 112 
were site and sex differences in methylomic drift, inter-individual heterogeneity, and whether 113 
drift patterns at the probe and CGI level reflect the expected variance of tissue sojourn times in 114 
the adenoma-to-carcinoma sequence. Estimates of adenoma-to-carcinoma times for rectum, 115 
distal, and proximal colon for the two sexes were based on mathematical models developed by 116 
our group to explain age-specific incidence patterns of CRC in the US and UK (26). (See Fig. 1).  117 
Here, we derive mathematical expressions for the distribution of total sojourn times from the 118 
occurrence of the premalignant founder cell to the descendent carcinoma, with these sojourn 119 
times properly conditioned on the time (patient age) when the descendent carcinoma is 120 
diagnosed and removed for molecular analysis.  121 
Of note, the premalignant sojourn times introduced here differ from clinical adenoma 122 
sojourn times (with varying estimates that range up to ~25 years (27)) as they capture the entire 123 
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phase of clonal expansion including the occult phase of the adenoma, the clinical (detectable) 124 
phase, and malignant phase that leads to symptomatic cancer. Hence, the difference is that the 125 
sojourn times we estimate date back to the premalignant founder cell that undergoes slow 126 
stochastic growth and does not become extinct.  127 
Finally, comparing CGI level methylomic drift with gene expression in CRC, we 128 
addressed the question whether methylomic drift may turn into a selective force impacting gene 129 
expression similar to our findings for EAC.  130 
Consortia and Patient Samples 131 
This study included normal colon and rectum samples obtained from patients participating in 132 
various studies in the Seattle-Puget Sound region, including the Luo Study (2), the Seattle 133 
ColoCare Study (28), the Screening Marker Study (SMS) (29), and GICaRes (GICR) (30). 134 
Written informed consent was obtained from all patients, the studies were conducted in 135 
accordance with recognized ethical guidelines (e.g., Declaration of Helsinki, CIOMS, Belmont 136 
Report, U.S. Common Rule) and the studies followed protocols approved by various Institutional 137 
Review Boards. (See Table 1).  138 
Experimental Plan/Study Design 139 
For discovery, we utilized SMS tissue samples (n=150) to identify significant DNA methylation 140 
drift (q-value 
410 ) at the CpG probe level. Tissue samples (n=68, left colon; n=14, right colon) 141 
from the independent GICR study were used to validate the discovered drift-CpGs, including 142 
analyses of drift differentials by sex and colorectal location both at the single CpG dinucleotide 143 
and CpG-island (CGI) level (with drift-CGIs defined as containing at least 5 drift CpGs per 144 
island).  Next, we obtained methylation data from endoscopic normal and cancer samples 145 
published by Luo et al. (2, 31) and The Cancer Genome Atlas (TCGA) consortium Colorectal 146 
Adenocarcinoma (COAD) and Rectum Adenocarcinoma (READ) projects (32, 33) to evaluate 147 
drift-related methylation patterns in neoplastic tissues. The TCGA data also included information 148 
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on the percentage of tumor cells that we used to adjust measured drift levels in the tumors for 149 
normal, stromal and necrotic cell content.  For TCGA data, we accessed the data via the 150 
Genomic Data Commons (level 1 HM450 methylation array idats) and for gene expression data 151 
via Firehose (Level 3, v2 pipeline, RSEM-normalized Illumina HiSeq 2000 gene expression 152 
counts, http://gdac.broadinstitute.org/, (34). All methylation array data were preprocessed as 153 
described in SI. 154 
Statistical software and data metrics 155 
Data pre-processing and most analyses were performed using the R programming language 156 
(v3.4.4) (35). The minfi Bioconductor package was used to analyze methylation data and 157 
preprocess idats as described previously (36).  158 
Levels of DNA methylation across islands and CpGs are provided as  -values (0 1  ), 159 
which represents the percentage of methylation at a given site or island, or as M-values, 160 
calculated as ( 2(logit  )). In keeping with our previous studies of methylomic drift in Barrett's 161 
esophagus, we preselected CpG probes that showed low levels of methylation ( 0.5  ) in 162 
normal tissue samples (17). See SI for further details.  163 
Data Availability 164 
Methylation data used in this study is deposited on the Gene Expression Omnibus, accession 165 
GSE113904. All other data were previously published in open-access repositories. 166 
Adenoma-to-carcinoma sojourn time distributions 167 
We previously published estimates for the mean sojourn time of an adenoma (from the birth of 168 
its founder cell) to cancer (13, 37). However, to correlate the methylomic drift in tumor tissue 169 
samples with tissue age, it is necessary to condition the estimate on the age when the cancer 170 
tissue sample was collected, while calculating the sojourn time as beginning with the initiating 171 
event that leads to the first premalignant cell that generates an adenoma and eventually the 172 
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cancer from which the tissue sample was collected. This is typically close to the patient age at 173 
the time of diagnosis. Here we provide a derivation of the sojourn time distribution conditioned 174 
on the age cancer is detected. Additional mathematical details can be found in previously 175 
published articles (38, 39). 176 
Given the age a cancer is detected clinically, two random events are assumed to occur 177 
prior to detection: (1) Initiation of a viable (premalignant) adenoma (referred to as a p-clone) that 178 
does not become extinct by the time it transforms to cancer and (2), a malignant transformation 179 
in the clonally expanding p-clone.  A third event, clinical observation of the carcinoma, coincides 180 
with the size-dependent detection of a malignant clone (m-clone) in the p-clone that forms the 181 
cancer. Let ( )Y t  be the (random) number of premalignant cells in a p-clone at time t  and 182 
0 1( | ( ) 0)f u Y t   be the conditional density function for the initiation of a p-clone (at time 1u ) that 183 
is conditioned on not becoming extinct prior to malignant transformation at time t . Further, let 184 
1( )p clonef t u   be the conditional density function for a p-clone to undergo a first malignant 185 
transformation in time length 1t u  that leads to a first cancer. Then, as shown in the SI, we 186 
have the following expression for the conditional density function of the initiating event that 187 
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.   (1) 189 
Here T
M
 represents the time when a malignant transformation occurs that will lead to a 190 
viable malignant clone and a clinically detected cancer at a later (random) time T
C
= a .  To 191 
account for this, we convolve the distribution in Eq. (1) over times TM=u2 for malignant 192 
transformation with the probability density for clinical detection of the malignant clone (m-clone) 193 
as a carcinoma at age T
C
= a . 194 
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u
g u T a du f a u f u T u    .  (2) 195 
Because multiple malignant transformations may occur during the lifetime of the 196 
adenoma before it turns into cancer, this formula is an approximation. However, as was shown 197 
in [13], this process can be well approximated by an effective malignant transformation in the p-198 
clone which generates a viable m-clone with transformation rate eff p   , where   is the 199 
rate for malignant transformations and p  is the asymptotic non-extinction probability (see SI 200 
for details).  201 
Explicit formulas for 0 1( | ( ) 0)f u Y t  , 1( )p clonef t u  , 2( )m clonef t u  , are provided in 202 
Supplemental Information (SI) (see Eqs S9, S11, and S13). The distribution of the adenoma 203 
initiation time 1u  given in Eq. (2) can then be used to compute the expected adenoma-to-204 
carcinoma sojourn times ( )E s  and their variance ( )Var s , conditioned on the carcinoma being 205 
detected at age CT a . Since 1s a u  , we have  206 
0
( ) ( | )
a
Ad CE s ds s g a s T a    (3) 207 
2
0
( ) ( ( )) ( | )
a
Ad CVar s ds s E s g a s T a    .       (4) 208 
Regression modeling of tumor methylation data  209 
We used a constrained non-linear regression model, corrected for the presence of normal and 210 
stromal cell fractions in the tumor samples, to fit the drift-CGI methylation levels of both TCGA 211 
and Luo tumors (excluding adenomas), separately for both sexes. The observed methylomic 212 
drift in these tumors was assumed to be the sum of an unobserved (true) neoplastic drift and 213 
drift associated with the non-tumor (normal/stromal) cell content in the sample.  Specifically, we 214 
used the following model to relate the mean methylation level D across the identified 781 drift-215 
CGI to the expected premalignant sojourn time E(s) , corrected for the measured fractions of 216 
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normal/stromal cells in the tumor samples, Nf , and with a fixed offset  representing the mean 217 
level of normal methylation at birth for all drift-CGI:  218 
𝐷 =  (1 − 𝑓𝑁) [𝜀 + 𝛼𝑇𝐸(𝑠)] + 𝑓𝑁 [𝜀 + 𝛼𝑁 𝐸(𝑎 − 𝑠)].         (5)                                             219 
Using this model, we estimated the CGI-level drift rate T  for the tumors, while the 220 
normal drift rate N across the 781 CGI was independently estimated using all normal tissue 221 
samples from the SMS and GICR studies.  Numerical values for the parameters in Eq. (5) and 222 
estimates of the tumor drift rate T  for males and females are provided in Table S1 in the SI. 223 
Variance of drift explained by stochastic cancer model 224 
To assess how much of the observed variance in drift in the Luo and TCGA CRC data can be 225 
explained by the variance associated with the stochastic colon cancer model, we computed for 226 
each sample the sum of square errors SSE =  (Dobs - Dexp)
2 , where Dexp is given by Eq (5) and 227 
Dobs the observed (mean) methylomic drift for a given sample. Thus, SSE is the sum of the 228 
square residuals of the data relative to the predicted age-dependent drift, adjusted for 229 
normal/stromal cell content in the tumor samples.  ‘Variance explained’ by the stochastic model 230 
is then computed as the ratio R=SSP/SSE, where SSP is the sum of square errors predicted by 231 
the stochastic model, i.e., SSP =  (T)
2Var(s). Thus, when 𝑅 < 1 the model cannot fully explain 232 
the observed variance while for 𝑅 > 1 the model yields a sojourn time variability that is 233 
inconsistent with drift data.  234 
Computer code 235 
R-code used to derive the following results is available on 236 
https://github.com/gluebeck/Epigenetic-Drift-in-Colon 237 
Results 238 
In this analysis, we: 1) identified and validated CpG probes that drift significantly in normal 239 
colorectal tissues; 2) examined the variability of drift in neoplastic tissues vs normal tissues (Luo 240 
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data); 3) determined corresponding drift rates at the CpG island (CGI) level defining drift-CGIs 241 
as CpG islands that contain at least 5 drift-CpGs; 4) compared drift rates by sex and colorectal 242 
location (proximal, distal, and rectum); 5) obtained island-level drift distributions in CRCs; and 6) 243 
computed the expected variability of drift observable in CRCs associated with the modeled 244 
distributions of premalignant (adenoma-to-carcinoma) sojourn times, defined by the time the 245 
ancestral premalignant progenitor cell is born until cancer diagnosis.  246 
Identification of methylomic drift at the CpG probe-level in normal colorectal tissue  247 
To identify age-related methylomic drift across a population of normal tissue samples, we 248 
performed probe-wise linear regressions using all 150 samples (both sexes) from the SMS 249 
study. Only probes with 0.5   across all samples were included in the discovery to select for 250 
positive drift, i.e. gradual increases of DNA methylation levels with age. This resulted in a total 251 
of 182,498 CpG probes being tested by regressing age (at the time of biopsy) on the  252 
methylation level (M-value) measured. Among these, we identified 13,525 probes with highly 253 
significant (mostly upward) drift (q-value 
410 ) as shown in Fig. 2.  254 
Furthermore, when these drift probes were evaluated separately in 41 normal tissue samples 255 
and 80 neoplastic tissue samples of the Luo study (2), we found that the methylomic drift was 256 
mostly associated with an increased variance in neoplastic tissues compared with normal 257 
tissues (Fig.2) suggesting a high level of tissue-age related heterogeneity in the neoplasia.  258 
Validation of methylomic drift in GICR study 259 
We used 68 additional normal (left colon) samples from the GICR study (30) to validate the set 260 
of drift-CpGs we identified in the SMS study (29). Although the SMS samples were exclusively 261 
collected in rectum, we found that out of the 13,525 drift-CpGs identified in SMS 12,700 could 262 
be validated as positively (drift rate 0 ) and significantly drifting in the GICR study (p-value 263 
0.05 ) using Pearson’s correlation. 264 
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Drift at the CpG-island (CGI) level 265 
Motivated by our recent findings of widespread epigenetic drift involving 1,000  CGI in Barrett's 266 
esophagus (18), we also evaluated age-related drift at the CGI level in colon and rectum. 267 
Among the 12,700 CpG probes that exhibited significant positive drift in both SMS and GICR 268 
data sets, we identified 871 CGI with at least 5 drift-probes per island (we will refer to such CGI 269 
as drift-CGI). As expected, island-level methylation was also highly correlated between the drift-270 
CGI in normal tissue (mean Pearson r=0.68), however it was attenuated in cancers (mean 271 
Pearson r=0.42 for left colon and rectum; r=0.55 for right colon in TCGA).  272 
To boost the overall correlations between drift-CGI, we selected a subset of 781 CGI 273 
that were consistently and significantly correlated with one another across TCGA cancers in 274 
both left and right colon. This filtering improved the mean drift-CGI correlations to 0.71 for 275 
normal colon, 0.46 for left colon and rectum, and 0.6 for right colon. However, we obtained 276 
similar results with the full set of 871 CGI.  277 
For the subset of 781 drift-CGIs, we list the genomic location, associated genes, proximity to 278 
transcription start sites (TSS200 or TSS1500), the number of array probes and number of 279 
identified drift probes and the island-level drift rate (regression slopes) in Table S2. For 280 
comparison, we also identified > 1000 CGI that do not appear to undergo methylomic drift in 281 
normal colon but that may or may not drift differentially in colorectal neoplasia. We refer to this 282 
comparison group as 'static-CGI'.  283 
 284 
 285 
Drift at the CpG-probe vs CGI-level  286 
While >90% of drift-CpGs identified are located within or near CGI, only 60% of all probes were 287 
associated with CGI on the array (i.e., are situated on an island, shore, or shelf), which shows 288 
that methylomic drift in normal colorectum (as defined here) occurs predominantly at islands. 289 
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Furthermore, drift rates appear to be more uniform at the island level compared with estimated 290 
drift rates at the single probe level (shown as drift-rate distributions by dashed and solid lines in 291 
Fig. 3 at the probe- and island-level, respectively).  292 
Next, to adjust for systemic differences in methylomic drift between the sexes, we 293 
performed an analysis of covariance (ANCOVA) allowing for differences in drift rates by gender 294 
(SMS and GICR left colon data, comparing 127 females and 91 males). Incremental differences 295 
in drift rates between males and females were statistically significant for 759 of 781 drift islands 296 
tested (q-value 0.05 ) and are shown by their distinct distributions for males and females in 297 
Fig. 3. 298 
Validating CGI level drift by gender and site 299 
Using ANCOVA regression with sex as a categorical variable and age as the continuous 300 
independent variable, we were able to validate island-level drift first identified in the SMS study. 301 
The GICR study comprised a total of 68 normal tissue samples from the left colon (31 males, 37 302 
females) and 14 normal tissue samples from the right colon (11 males, 3 females). 303 
All GICR samples were from cancer-free patients at the time of biopsy. Fig. 4 shows the 304 
estimated drift rates for the two studies by gender. The drift rate distributions for males and 305 
females in the left colon are clearly distinct for the two sexes with males showing 40% (SMS) 306 
and 65% (GICR) higher mean drift rates compared with females. Due to small sample size, only 307 
results for males and females combined are shown in Fig. 4 for methylomic drift in right 308 
(proximal) colon (gray symbols).  309 
 310 
Methylomic drift in neoplastic tissues 311 
The expected sojourn times E(s) of the parental adenoma that led to the clinically detected 312 
cancers and measured methylation drift rates (adjusted for tissue composition) are shown for 313 
males in Fig. 5A and 5B, respectively, by age and anatomical site together with their 95% 314 
Research. 
on November 13, 2018. © 2018 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 5, 2018; DOI: 10.1158/0008-5472.CAN-18-1682 
confidence bands.  Similarly, Fig. 5C and 5D show female expected parental adenoma sojourn 315 
times and adjusted methylation drift rates, respectively. The parameters used for these 316 
predictions are taken from Meza et al. (26) who fitted 3-stage clonal expansion models to 317 
colorectal incidence data in the US and the UK. Although the model parameters (adjusted for 318 
secular trends) were similar for the US and UK, we chose to use the model parameters obtained 319 
for the UK population, which historically had lower colorectal screening utilization than the US, 320 
therefore better reflect the natural history of CRC. Note, the computed age-specific sojourn 321 
times do not differ significantly between males and females for neoplasia in right (proximal) 322 
colon and rectum. For neoplasia in left (distal) colon we obtained sojourn times that are between 323 
those for rectal and proximal colon among males (Fig. 5A) but are more similar to the sojourn 324 
times in rectal colon among females (Fig. 5C). However, for all sites and the two sexes, our 325 
predictions suggest that adenoma bound for cancer started early in life, most likely before the 326 
age of 20. See Fig. 5A and 5C and Fig. S1 in SI. 327 
 To see whether our sojourn time estimates are consistent with methylomic drift patterns 328 
in neoplasia, we assumed constant drift rates and fitted them by regressing drift-related 329 
methylation levels (at the island-level) on patient age using the computed age-, sex- and site-330 
specific premalignant sojourn times (see Material and Methods). The estimated neoplastic drift 331 
rates (M-value/year), although similar for the 3 anatomical sites, were about 12-22% higher in 332 
males than females (proximal colon – females/males: 0.056/0.065, distal colon: 0.054/0.061, 333 
rectum: 0.051/0.061). This difference is not unexpected since we found much stronger drift rate 334 
differences between the sexes in normal colorectum (Fig. 3). Of note, (1) although the corrected 335 
drift patterns shown in panels B (males) and D (females) of Fig. 5 still exhibit a high degree of 336 
variability compared with the expected variance, especially for proximal (right) colon, we 337 
observe that the ordering of the drift patterns and their fits closely follow the predicted ordering 338 
of premalignant sojourn times in panel Fig. 5A and 5C. (2) the estimated island-level drift rates 339 
that best fit the methylomic patterns shown in panel 5B (males) and panel 5D (females) are 340 
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similar for the 3 sites and are approximately 3 to 4-fold higher than the corresponding drift rates 341 
for normal colon. (3) our estimates of a roughly 3 to 4-fold acceleration of methylomic drift in 342 
colorectal neoplasia is consistent with various cell proliferation measurements (discussed 343 
below) in normal colorectal epithelium vs adenoma and carcinoma, suggesting that the 344 
epigenetic drift (as defined here) is likely correlated with mitotic activity (23, 40-42). 345 
Methylomic tissue age (mAge) vs drift-based sojourn time predictions 346 
Several ‘universal’ methylomic clocks have been introduced recently to predict biological tissue 347 
age using regularized regression methods (24, 25). In contrast to the drift-based clock used for 348 
this study, which scans individual CpG probes for significant correlations with age, these multi-349 
tissue-type clocks primarily rely on elastic net regressions to predict chronological age from a 350 
selection of CpG probes. To compare sojourn time estimates for the TCGA samples included in 351 
this study (using Eq (5)) with estimates of mAge provided by others, we computed mAge for two 352 
published clocks by Horvath (Horvath 1: 353 CpGs; Horvath 2: 110 CpGs) and a clock 353 
developed by Hannum et al. (71 CpGs) (24, 25). All estimates were adjusted for normal cell 354 
content assuming that the normal cell fraction in the tumors contributes a term proportional to 355 
patient age. Table S3 shows the correlations between our predicted sojourn times and mAge for 356 
the 3 models, as well as their means and p-values for difference in mean mAge and mean E(s) 357 
= 61 years of the 322 TCGA colorectal samples used for this comparison.  We find significant 358 
correlations of mAge with our predictions (r = 0.45, p-value < 2.2  10-16 for the Hannum et al. 359 
clock). Moreover, upon a simple recalibration of the unadjusted mAge estimates of normal 360 
tissue to closely fit patient age, this clock also predicts excessively long sojourn times. In 361 
contrast, while the Horvath 110 CpG clock still provides good correlations with our sojourn time 362 
predictions (r = 0.32, p-value = 6.9 10-9), the 353 CpG clock correlates only poorly (r=0.07, p-363 
value = 0.2).  364 
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Degree of methylomic drift in cancers shows strong correlation with methylation levels in 365 
normal tissue To compare drift patterns at the CGI-level between normal and cancer tissue, we 366 
ordered the samples by their mean methylation levels across the drift-CGI in normal colon 367 
tissue (Fig. 6). The resulting heatmaps (for left colon in Fig. 6, for right colon in Fig. S2) show 368 
that the base-level of methylation in normal colon is predictive of the amount of drift occurring in 369 
cancers.  CGI that are static (first 300 top rows) in normal colon do not drift discernibly in 370 
cancers (although they can be altered).  In contrast, CGI that drift in normal colon show 371 
accelerated drift in cancers with increasing levels of methylation in normal tissue (Fig. S3). The 372 
correlation between mean drift in normal tissue and mean drift in the cancer tissues across the 373 
781 drift-related islands is 0.81 (p-value 
162.210 ).  In contrast, static CGI, defined here as 374 
islands that comprise at least 5 CpG probes found not to undergo drift in normal colon (drift 375 
rates 0.002 / year, shown as light grey data points in Fig. 2), do not drift in the cancers (Fig. 376 
S4). 377 
Methylomic drift and gene expression 378 
We previously found that advanced methylomic drift on some CGI associated with actively 379 
transcribed genes in EAC are significantly associated with reduced gene expression and 380 
possibly gene silencing (18).  Thus, here we investigated whether methylomic drift in CRC is 381 
similarly associated with widespread transcriptional repression.  To this end, we computed the 382 
Pearson correlation between methylation and gene expression (RNA-seq) and its statistical 383 
significance for all gene-CGI pairs for left colon ( 184n  , including rectum) and right colon 384 
cancers ( 138n  ) from the TCGA. Out of a total of 668 identified gene-island pairs in right colon 385 
we found 373 (56%) of pairs that show a significant negative Pearson correlation, while only 34 386 
(5%) of pairs show a significant positive correlation (q-value 0.01 ).  In contrast, left colon 387 
cancers show fewer pairs being correlated.  Out of a total of 663 identified gene-CGI pairs in left 388 
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colon we found only 170 (26%) pairs that show a significant negative correlation, while 46 (7%) 389 
pairs show a significant positive correlation (q-value 0.01 , see Table S4).  390 
Although the overall number of correlated gene-CGI pairs in right colon is almost twice 391 
the number in left colon, 78% (169/216) of the pairs in left colon are also found to be 392 
significantly correlated in right colon.  Furthermore, we find no significant difference in the 393 
fractions of repressed vs over-expressed genes affected by drift in the right vs left colon (p-394 
value = 0.24, Fisher’s exact test). For comparison, we identified >1000 islands that appear 395 
’static’ in normal colon tissue (see Fig. 2) and do not show discernible age-related drift among 396 
cancers (Fig. 6 and Figs. S2 and S3).  Surprisingly, 16%  (19% ) of these static islands in left 397 
(right) colon also show strong correlations between methylation and gene expression 398 
suggesting that they, albeit under stronger epigenetic control in normal tissue, can also be 399 
altered in neoplasia and may participate in the clonal evolution of a cancer (see Table S5). 400 
However, compared to gene-CGI pairs that are associated with methylomic drift and exhibit 401 
significant methylation-gene expression correlations in the cancers, fold-changes (> 2-fold up or 402 
down) in expression are less common among static pairs (<25%) compared with drift pairs (> 403 
62%) in left and right colon. 404 
 405 
Discussion 406 
Methylomic drift appears to be widespread in normal colon and rectum, involving at least 7% of 407 
CpG probes tested (q-value
410 ). Over 90% of these probes are found on (or near) CGI, while 408 
only 64% of HM450 probes are located on or near CGI. However, among probes with  < 0.5 in 409 
normal colorectum, the fraction of HM450 probes on or near islands is about 88%, similar to the 410 
fraction of drift-CpGs we identified. In contrast, a study by Irizarry et al. (43) of the human colon 411 
cancer methylome showed that aberrant methylation predominantly occurred at conserved 412 
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tissue-specific CGI shores, with hypermethylation typically enriched closer to the associated 413 
CGI and hypomethylation enriched further from the associated CGI. While this finding appears 414 
in conflict with our findings of drift occurring mainly on (or near) CGI, we point out that our 415 
definition of CGI includes the shore regions which extend 2kb from the island boundaries. Thus, 416 
the island-level drift (including shore regions) in neoplastic tissue observed in our study, is not 417 
inconsistent with the tissue-specific methylation changes in cancers observed by Irizarry et al. 418 
(43) and may well play an important role in the phenotypic evolution of cancer.   419 
 420 
Several important conclusions can be drawn from our findings:  421 
(1) Methylomic drift in normal colon continues unabated at an increased rate in neoplastic tissue 422 
(about 3-4 fold faster compared with normal colon), with drift-associated methylation in proximal 423 
colon showing the highest gains across the older aged (age >60) cancer population, followed by 424 
distal colon and with rectum showing the lowest gains. However, the estimated drift rates for 425 
neoplasia in these sites are similar which suggests that, on average, neoplastic lesions in the 426 
proximal colon sojourn longer than lesions in the distal colon and rectum. This conclusion is 427 
consistent with the findings from independent mathematical modeling of age-specific incidence 428 
curves of CRC in the US and UK (26) that suggested significantly slower growth rates of 429 
proximal adenoma compared with distal and rectal adenoma.  430 
(2) Several studies have carefully measured cell proliferation in both normal and neoplastic 431 
(adenoma) colon mucosae.  The study by Kikuchi et al. (44) evaluated the Ki-67 (MIB-1) cell 432 
proliferation marker in normal colon, adenoma of various histology, and carcinoma. Although Ki-433 
67 labeling is strongly dependent on cell position within crypts, Ki-67 labeling in normal colon 434 
was 14% 5%  while in adenoma Ki-67 was 26.5% 9%  for low grade adenoma and 435 
35% 6%  for high grade adenoma in the Kikuchi et al. study, suggesting a 2-3-fold increase in 436 
cell proliferation between normal and neoplastic colon tissue.  In carcinoma, Ki-67 labeling is 437 
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about 3-fold higher than normal tissue (53% 5% ).  Similarly, the study by Baker et al. (45) 438 
found 3-fold increase in the number of Ki-67+ cells at the crypt base in adenomatous colon 439 
tissue that lost APC, compared with wild-type normal colon.  440 
(3) The computed age-dependent sojourn time distributions for proximal colon, distal colon, and 441 
rectum indicate that the first premalignant cell that generates a cancer-forming adenoma 442 
typically arises early in life and may take decades before developing into cancer. This 443 
conjecture is supported by our analysis of methylomic drift in colorectal neoplasia relative to 444 
normal colon tissue which shows that drift rates in neoplastic colon are increased similarly to 445 
independently measured rates of cell proliferation in adenoma and carcinoma compared with 446 
those in normal colon (44).  Furthermore, an independent application of 3 universal (multi-447 
tissue-type) clocks yields similarly long time scales (~60 years) for the TCGA samples analyzed 448 
in this study (Table S3) with 2 of the 3 clocks showing significant correlations with the computed 449 
drift-based sojourn times.   450 
(4) Although methylomic drift appears highly variable in the tumors (even after correction for 451 
normal/stromal cell content), 55-89% of the total (island-level) variance in DNA methylation 452 
observed in the tumor samples can be attributed to the stochasticity of the tumor growth 453 
process and random events that lead to a cancer and its detection. Note, this range of variability 454 
explained by the model does not account for any variability present in normal tissue prior to 455 
adenoma initiation. However, a variance analysis of methylation levels of static CGIs in normal 456 
tissues compared with variances of drift-CGI in normal and cancer tissues indicates that the 457 
normal sample population has a constant (non-drift) variance of about 0.018, which increases 458 
>3-fold for drift-CGI to 0.07, while in cancers this variance increases to about 0.36. Thus, 459 
assuming static methylomic variability across samples approximates the variability at adenoma 460 
initiation, only ~5% (0.018/0.36) of the observed drift variance across cancers may be attributed 461 
to pre-existing methylomic variability in normal tissue.   462 
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(5) Consistent with findings of a recent analysis of methylomic drift in Barrett’s esophagus and in 463 
esophageal adenocarcinoma (18), we found that advanced methylomic drift at the islands-level 464 
is frequently (> 50% in right colon, > 25% in left colon) associated with significant reductions in 465 
gene expression. We identified only a small number of drift-related CGI-gene pairs for which 466 
drift correlated positively with gene expression (e.g., SIM2, TBX5, see Table S4). Although our 467 
analysis does not demonstrate causality, the fact that epigenetic drift of CGI in normal colon is 468 
more prominently associated with transcriptional changes in colorectal neoplasia than static CGI 469 
that undergo little or no drift in normal colorectum suggests a potential role of methylomic drift in 470 
the clonal evolution to cancer. 471 
Our study has several limitations related to the nature of the available data, their clinical 472 
annotation and the methylation array platform used. In particular, the HM450 platform only 473 
covers a small fraction (~1.6%) of CpGs in the human genome and has an uneven distribution 474 
of CpGs at the island level. Thus, our selection of drift-CpGs is biased toward islands with a 475 
larger number of array probes likely resulting in an underestimation of genome-wide methylomic 476 
drift. Furthermore, we lack gene expression data for our normal tissue samples (GICR, SMS 477 
and Luo study) preventing a comparative study of drift-related phenotypic changes in normal vs 478 
neoplastic tissue. Although, we are able to explain up to 77-89% of the observed methylomic 479 
variance of drift-CGI in distal colon and rectum, we only explain a much smaller fraction (55%) 480 
of this variance in proximal colon. It is conceivable that other unaccounted factors contribute 481 
differentially to the observed variance including environmental exposures, diet, microbiome, 482 
immune status, cancer (epi)genetics and measurement errors. Unfortunately, most of these 483 
covariates are unavailable in our data and TCGA and have not been included in the modeling of 484 
the adenoma sojourn times.  In spite of the limitations of the modeling and lack of further data 485 
that more fully explain the observed inter-individual heterogeneity in methylomic drift in these 486 
samples, our results support the hypothesis that adenoma that lead to cancer arise early in life, 487 
even for CRCs that occur at advanced ages. Thus, starting chemoprevention and lifestyle 488 
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interventions early in life (rather than later in life) may be more effective in reducing the cancer 489 
burden given our findings that cancer precursors likely sojourn for decades before turning into 490 
cancer.        491 
In summary, our analysis shows that age-related methylomic drift is a genome-wide 492 
phenomenon that occurs in normal colon and continues at an accelerated pace in colorectal 493 
neoplasia. Furthermore, we show that differences in age-related drift between normal and 494 
neoplastic tissues are broadly consistent with predicted long-duration but individually variable 495 
total adenoma-carcinoma sojourn times that capture approximately 55-89% of the variance of 496 
drift-CGI heterogeneity in CRCs. Other factors, including those related to genetics, obesity, diet, 497 
lifestyle and environmental factors and use of chemo-preventative agents such as use of non-498 
steroidal anti-inflammatory drugs (NSAIDS) may account for much of the remaining 499 
heterogeneity. Importantly, the estimated long duration of premalignant sojourn times suggests 500 
that CRC incidence may be reduced through early (and ideally lifelong) dietary and lifestyle 501 
interventions.  502 
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Tables  694 
Study Number of Colorectal location Sex Mean age at Sample Patient 
group samples Rectum Left Right F/M diag. (range) histology status 
SMS 150 150 0 0 90/60 58.1 (31 - 79) normal healthy 
GICaRes 82 0 68 14 40/42 60.9 (29 - 82) normal healthy 
Luo (normal) 41 unknown unknown unknown 19/22 58.4 (43 - 78) normal matched (n=24) 
Luo 
(neoplasia) 





TCGA 322 43 141 138 145/177 64.9 (31 - 90) cancer cancer 
 695 
Table 1: Study, number of samples, sample location and mean patient age (range) used for this 696 
study. Note: we excluded EACs from The Cancer Genome Atlas (TCGA) with MSI and/or 697 
mucinous histology. 698 
Figure Legends 699 
Fig. 1:  DNA methylation drift measured in a cancer tissue sample provides a measure of the 700 
sojourn time between initiation of the founder premalignant cell and the cancer that arises along 701 
this lineage. Premalignant clones may grow gradually for decades prior to generating an 702 
observable adenoma or cancer. 703 
Fig. 2. Estimated CpG drift rates of 182,498 CpG probes vs the (log2) ratio of methylation 704 
variance in tumor samples relative to the corresponding variance in normal tissue samples from 705 
the Luo study [11]. Variances and drift rates were computed using M-values. The drift rates 706 
were estimated using linear regression of methylation vs patient age (in years). CpGs in dark 707 
grey undergo significant methylomic drift (q-value <10-4), CpGs in medium grey are considered 708 
static, i.e., do not show significant linear trends with patient age. The subset of CpGs marked in 709 
light grey serves as a control group for the analysis of gene expression and methylomic drift 710 
(see Results).    711 
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Fig. 3. Drift rate distributions in SMS for 781 CGI with a minimum of 5 identified drift-CpGs by 712 
sex (solid curves) versus analogous distributions at the probe-level comprising 12,700 CpGs 713 
(dashed curves). 714 
Fig. 4. Boxplots of the drift rate distributions for the same CGI as in Fig.(2), but validated in 715 
samples from the GICR study for left (distal) and right (proximal) colon samples. For each group 716 
the individual drift rate estimates are shown as data points. Due to small sample sizes for males 717 
and females in right colon, drift rates were determined for both sexes combined in right colon. 718 
Fig. 5. A) Expected (mean) premalignant sojourn times (in years) for males by age of cancer 719 
diagnosis and anatomical site with 95% confidence bands, based on the model fits described in 720 
Meza et al. [10] for UK males. B) Sojourn time-dependent drift curves fitted to normal/stromal 721 
cell content corrected TCGA (solid symbols) and Luo (empty symbols) methylomic CGI-level 722 
drift in tumors by sex and anatomical site. Regression model described in Material and 723 
methods. C, D) same as A and B, respectively, but for females. 724 
Fig. 6. Methylation heat map of 300 static CGI (top rows) and 781 drift-related CGI (bottom 725 
rows) for 68 normal samples and 141 TCGA colon cancer samples (left colon only).  Sample 726 
groups (normal, cancers) are shown ordered by their mean island level methylation. 727 
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